All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubGVhD HubLymphoma HubMDS HubMPN HubMultiple Myeloma

Which AML patients benefit most from treatment with CPX-351?

The AML Hub was pleased to speak with Jeffrey E. Lancet, Moffitt Cancer Center, Tampa, US. We asked, Which AML patients benefit most from treatment with CPX-351?

Which AML patients benefit most from treatment with CPX-351?

Lancet begins by describing factors that affect treatment choices for patients with AML, especially the patient goals. He outlines the use of CPX-351 as primary induction therapy, its challenges, benefits, and main candidates. Finally, Lancet discusses oral azacitidine and the changing landscape of AML therapies.

 

Share:
More about...